FDA approves weekly diabetes therapy Bydureon

01/29/2012 | New York Times (tiered subscription model), The

Amylin Pharmaceuticals and Alkermes' Bydureon, or exenatide, was approved by the FDA as a once-weekly treatment for type 2 diabetes. The glucagonlike peptide-1 receptor agonist costs about $4,200 a year. Amylin is conducting an FDA-requested trial to determine whether Bydureon heightens the risk of heart attacks, thyroid cancer and pancreatitis.

View Full Article in:

New York Times (tiered subscription model), The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX